S. Nagdas

发表

Electrophysiology-based stratification of pancreatic tumorigenicity by label-free single-cell impedance cytometry.

N. Swami, V. Farmehini, W. Varhue, 2020, Analytica chimica acta.

ISL2 is an epigenetically silenced tumor suppressor and regulator of metabolism in pancreatic cancer

Mazhar Adli, N. Bardeesy, Cem Kuscu, 2020, bioRxiv.

Headless Myo10 Is a Negative Regulator of Full-length Myo10 and Inhibits Axon Outgrowth in Cortical Neurons*

R. Cheney, M. Kerber, S. Nagdas, 2012, The Journal of Biological Chemistry.

CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer

J. Parsons, C. Slingluff, K. Ravichandran, 2017, Clinical Cancer Research.

ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer.

Mazhar Adli, N. Bardeesy, D. Ting, 2022, Developmental cell.

The Interplay between Oncogenic Signaling Networks and Mitochondrial Dynamics

David F. Kashatus, S. Nagdas, 2017, Antioxidants.

Beta-Catenin Regulated ALDH1A1 is a Target in Ovarian Cancer Spheroids

D. Matei, S. Condello, J. Turek, 2014, Oncogene.

Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor Growth

David F. Kashatus, E. Stelow, H. Sesaki, 2019, Cell reports.

miR‐206 family is important for mitochondrial and muscle function, but not essential for myogenesis in vitro

Anindya Dutta, David F. Kashatus, P. Przanowski, 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

miR-206 family is important for mitochondrial and muscle function, but not essential for myogenesis in vitro

Anindya Dutta, David F. Kashatus, P. Przanowski, 2019, bioRxiv.

Identifying metabolic adaptations during cardiotoxicity using paired transcriptomics and metabolomics data integrated with a model of heart metabolism

Kristopher D. Rawls, Matthew L. Jenior, Bonnie V. Dougherty, 2021 .

Beta-Catenin Regulated ALDH1A1 is a Target in Ovarian Cancer Spheroids

D. Matei, S. Condello, J. Turek, 2014, Oncogene.

Survival benefit associated with screening of patients at elevated risk for pancreatic cancer.

V. Zaydfudim, V. Shami, S. Nagdas, 2024, Journal of surgical oncology.

Identifying metabolic adaptations characteristic of cardiotoxicity using paired transcriptomics and metabolomics data integrated with a computational model of heart metabolism

Kristopher D. Rawls, Matthew L. Jenior, Bonnie V. Dougherty, 2024, PLoS Comput. Biol..

Deciphering the FGFR2 Code: Innovative Targets in Gastric Cancer Therapy

S. Nagdas, Alireza Tojjari, A. Saeed, 2024, Current oncology.